Qiagen N.V. (QGEN) Stock Price & How to Invest

Last updated November 2026

Short answer

QGEN is QIAGEN N.V., a Netherlands-domiciled, NYSE-listed molecular diagnostics and sample-technology company that sells DNA/RNA extraction kits, PCR chemistries, and diagnostic instruments to labs worldwide. It trades as a steady, cash-generative life-sciences play whose growth hinges on its QIAstat-Dx syndromic testing and Sample technologies franchises offsetting a soft QuantiFERON tuberculosis line. As of 2026-11-20 the shares closed near $49.46, up ~9% in 2026 and ~8% over one year, for a market value of ~$10.2 billion. Shareholders approved Jonathan M. Pratt in November 2026 to succeed Thierry Bernard as CEO.

QGEN stock price

As of 2026-11-20, Qiagen N.V. (QGEN) last closed at $49.30, up 5.3% over the past year. Over the past 52 weeks it has traded between $32.63 and $55.66.

QGEN last close
$49.30
1 day
-0.66%
1 month
-1.40%
1 year
+5.25%
52-week range
$32.63 to $55.66
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Qiagen N.V.'s investor relations page. Walnut is informational, not investment advice.

QGEN key stats

At $49.30 on November 20, 2026, Qiagen N.V. (QGEN) has a market cap of $10.2B, a P/E of 26.7 on trailing earnings (18.5 on forward earnings) and a dividend yield of 0.71%. It next reports earnings around February 3, 2027 (estimated).

Market cap
$10.2B
P/E (trailing)
26.7
P/E (forward)
18.5
EPS (trailing 12 months)
$1.85
Price to book
2.9
Dividend yield
0.71%
Beta
0.56
Next earnings
around February 3, 2027 (estimated)

Market cap, P/E and yield are measured at the $49.30 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Qiagen N.V. (QGEN)?

The last two weeks for Qiagen N.V., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • QGEN closed at $49.30 on November 20, 2026, down 1.2% over the past five trading days (from $49.89).
  • Qiagen N.V. next reports quarterly results around February 3, 2027 (estimated).
  • On November 13, 2026, UBS raised its target to $50.00 from $48.00 (Neutral).

Qiagen N.V. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Qiagen N.V. (QGEN) do?

QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.

The investment picture is one of a defensive, recurring-revenue diagnostics supplier navigating a mixed demand backdrop. In Q1 2026, reported sales rose about 2 percent to roughly $492 million, but constant-currency sales slipped about 1 percent as weaker QuantiFERON volumes and cautious U.S. Life Sciences demand offset 9 percent constant-currency growth in Sample technologies and strong QIAstat-Dx placements. Management trimmed full-year 2026 guidance to about $2.43 adjusted EPS on roughly $2.1 billion of sales, below prior consensus, framing QGEN as a margin-disciplined operator whose thesis rests on high-growth diagnostics platforms scaling faster than the legacy drags.

The next two quarters steadied the picture. Sales for the quarter ended June 30, 2026 were ~$535 million, roughly flat year over year, with adjusted EPS of $0.62 against a ~$0.60 consensus. The September quarter was firmer still: sales of ~$548 million, up ~2.9% year over year, and adjusted EPS of $0.65 against ~$0.63 expected, with net income of ~$106 million. Along the way QIAGEN added U.S. FDA clearances that complete its QIAstat-Dx bloodstream infection (sepsis) portfolio, launched the QIAmini instrument to automate small-batch sample preparation, and expanded its AI-powered bioinformatics tools for research and drug discovery. Barclays upgraded the stock to Overweight in early October 2026, and in November shareholders approved Jonathan M. Pratt as the next CEO and Managing Director, succeeding Thierry Bernard. As of 2026-11-20 the market value is ~$10.2 billion; consensus now has 2026 adjusted EPS at ~$2.49, a little above the earlier ~$2.43 guidance, and the next report is expected around February 3, 2027.

What's driving Qiagen N.V. (QGEN)?

1. QIAstat-Dx syndromic testing

QIAstat-Dx, QIAGEN's cartridge-based syndromic panel system, has been a standout with strong constant-currency growth and heavy new-instrument placements. Menu expansion across respiratory, gastrointestinal, and other panels drives recurring cartridge pull-through. Each placed analyzer creates an annuity of consumable sales, making installed-base growth a leading indicator. In late September and early October 2026 the FDA cleared new QIAstat-Dx panels that complete its U.S. bloodstream infection portfolio, widening the menu that each installed analyzer can run.

2. Sample technologies and single-cell

Sample technologies (collection, stabilization, purification, and quality control consumables) grew about 9 percent at constant currency in Q1 2026, its fastest-growing pillar. The December 2025 Parse Biosciences acquisition extends this franchise into single-cell analysis. New sample-preparation instruments planned for 2026 aim to deepen lab automation and standardized workflows; the first, QIAmini, launched in September 2026 to automate small-batch sample preparation.

3. Margin discipline and capital returns

QIAGEN has emphasized product rationalization and cost control to protect adjusted operating margins even as top-line growth runs in the low single digits. The company held its full-year profit targets in Q1 2026 despite the revenue softness, then beat adjusted EPS consensus in Q2 and Q3. Steady free cash flow supports buybacks and bolt-on acquisitions. Trailing free cash flow is ~$373 million, and the company pays a small dividend (~0.7% yield).

4. Diagnostics mix shift

The company is steering revenue toward higher-value molecular diagnostics and away from lower-growth research categories through its five-pillar 2028 strategy. Companion-diagnostic partnerships (for example with DiaSorin and Incyte) and QIAcuity digital PCR broaden the clinical footprint. A richer diagnostics mix can lift durable growth and pricing power over time.

What are the risks to Qiagen N.V. (QGEN)?

QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks: even after a firmer September quarter, sales grew only ~2.9% year over year, and consensus for 2027 is ~7% revenue growth. Net debt is real (~$1.65 billion of debt against ~$833 million of cash), though manageable against ~$751 million of trailing EBITDA. QIAGEN itself has flagged new pressures on global tuberculosis programs, which matter directly to QuantiFERON demand. A change of CEO, with Jonathan M. Pratt succeeding Thierry Bernard, can bring shifts in strategy or priorities, and integration of acquisitions like Parse Biosciences carries execution risk.

What is the Qiagen N.V. (QGEN) forecast?

11 analysts publish price targets on QGEN, averaging $49.77 as of November 2026, or +1.0% against the $49.30 share price on November 20, 2026. The published targets run from $40.00 to $53.00, a narrow spread, and the ratings split 1 buy, 11 hold, 0 sell. Over the last six months there have been 9 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full QGEN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is QGEN a buy or a sell?

We give no verdict on Qiagen N.V.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. QIAstat-Dx syndromic testing. QIAstat-Dx, QIAGEN's cartridge-based syndromic panel system, has been a standout with strong constant-currency growth and heavy new-instrument placements. The most optimistic published target, $53.00, assumes this works close to its best case.

The case against. QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. The most pessimistic target, $40.00, is roughly what QGEN is worth if this bites instead.

Read the full bull and bear case on QGEN, including what would have to change to break either one. Walnut is not an investment adviser.

Has Qiagen N.V. (QGEN) split its stock?

Yes. Qiagen N.V. (QGEN) has had one share split in the last 10 years:

  • 962:1000 on January 25, 2017, so every share held became 0.962 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of QGEN the day before the 962:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

How is Qiagen N.V. (QGEN) valued?

Market cap, P/E and dividend yield at today's price are in the QGEN key stats above. The business figures below come from Qiagen N.V.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$2.1B (sales growth ~2.9% YoY in Q3 2026)
  • Latest quarter (Q3 2026): Sales ~$548M (+2.9% YoY); adjusted EPS $0.65 vs ~$0.63 expected
  • Margins (gross / operating, TTM): ~67% / ~27%
  • Net income (TTM): ~$385M

As of November 2026: At ~$10.2 billion and ~19x forward earnings, QGEN is valued as a steady compounder: consensus has 2026 adjusted EPS at ~$2.49 on ~$2.14 billion of sales, rising to ~$2.67 in 2027 on ~7% revenue growth. The stock has re-rated since mid-2026 (up ~13% over three months and ~9% in 2026) after two quarterly beats and the Barclays upgrade, and analysts' average target of ~$49.77 now sits almost exactly at the ~$49.46 price. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.

Which ETFs hold Qiagen N.V. (QGEN)?

If you want QGEN exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in QGENExpense ratio
DFISDimensional International Small Cap ETF0.5%0.39%

Who competes with Qiagen N.V. (QGEN)?

Large diversified life-sciences and diagnostics

Thermo Fisher Scientific and Danaher (Cepheid, Beckman) overlap heavily with QIAGEN in sample prep, PCR chemistries, and molecular diagnostics, with far larger scale and R&D budgets. Thermo Fisher once agreed to acquire QIAGEN before the deal collapsed; the episode was a reminder of how much the two companies' workflows overlap.

Clinical molecular diagnostics platforms

Roche, Abbott, Siemens Healthineers, and bioMerieux dominate high-volume clinical molecular and syndromic testing, competing with QIAstat-Dx and QuantiFERON. Roche in particular commands a global installed base in molecular and immunoassay systems that QIAGEN must displace lab by lab.

Genomics and sequencing

Illumina leads next-generation sequencing, an area where QIAGEN participates through library prep, bioinformatics (QIAGEN Digital Insights), and sample technologies rather than sequencers. Single-cell entrants and NGS-adjacent players also compete following the Parse Biosciences acquisition.

What stocks are similar to Qiagen N.V. (QGEN)?

Other names that sit close to QGEN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Qiagen N.V. (QGEN)

There are three common ways to get QGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DFIS), which spreads the position across many companies. Or build it into a focused thematic portfolio, so QGEN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where QGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Qiagen N.V. (QGEN)

QGEN is a profitable, diversified diagnostics and sample-prep supplier priced as a mid-teens-multiple compounder, not a high-growth name: ~19x forward earnings and ~27x trailing as of November 2026, on ~$2.1 billion of trailing revenue that grew ~3% in the latest quarter. The appeal is recurring consumable revenue, ~67% gross margins and a steady stream of QIAstat-Dx menu approvals; the limit is low-single-digit growth, a QuantiFERON drag that keeps the top line from accelerating, and a CEO handover that brings a new leader to the 2028 plan.

More on Qiagen N.V. (QGEN)

Whether QGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is QGEN a buy or a sell?, and where the stock could go from here in the QGEN stock forecast.

For income investors, whether QGEN pays a dividend and how the payout looks is covered in does QGEN pay a dividend? And to weigh QGEN against a peer, read the full side-by-side comparisons: QGEN vs TMO and QGEN vs DHR.

Wondering how QGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Qiagen N.V.

Ask Walnut's AI anything about QGEN and see how it fits what you own.

FAQ

What does QIAGEN do?

+

QIAGEN provides sample and assay technologies for molecular testing. It sells consumables and instruments that collect, purify, and analyze DNA and RNA, plus molecular diagnostic platforms like QIAstat-Dx and QuantiFERON used by labs in diagnostics, research, and pharma.

Is QGEN a US or foreign stock?

+

QIAGEN N.V. is legally domiciled in the Netherlands with German roots, but its shares trade on the NYSE under QGEN (and also in Frankfurt). At a ~$10.2 billion market value in November 2026, it is a large, established multinational, not a foreign shell or thinly traded OTC listing.

How did QIAGEN perform in Q1 2026?

+

Reported sales rose about 2 percent to roughly $492 million, but constant-currency sales fell about 1 percent as weaker QuantiFERON and cautious U.S. Life Sciences demand offset strong Sample technologies and QIAstat-Dx growth. Adjusted EPS came in around the low end of guidance. The following quarters were firmer: Q2 2026 sales were ~$535 million with adjusted EPS of $0.62 (vs ~$0.60 expected), and Q3 sales were ~$548 million with $0.65 (vs ~$0.63).

What is QIAGEN's 2026 guidance?

+

Management guided full-year 2026 to roughly $2.1 billion in sales and about $2.43 in adjusted EPS, both below prior consensus at the time. The company held its profit targets despite trimming the revenue outlook, citing margin discipline against soft demand. After beats in Q2 and Q3, the analyst consensus as of November 2026 sits at ~$2.49 of adjusted EPS on ~$2.14 billion of sales, with the December quarter expected at ~$570 million of sales and ~$0.66 of EPS.

What are QIAGEN's main growth drivers?

+

Its fastest-growing areas are QIAstat-Dx syndromic testing (strong instrument placements and cartridge pull-through) and Sample technologies, which grew about 9 percent at constant currency in Q1 2026 and now includes single-cell analysis after the Parse Biosciences acquisition.

Who are QIAGEN's main competitors?

+

It competes with Thermo Fisher and Danaher in sample prep and PCR, with Roche, Abbott, Siemens Healthineers, and bioMerieux in clinical molecular diagnostics, and touches genomics markets led by Illumina. Most rivals are substantially larger.

How is QGEN valued?

+

At roughly a $10.2 billion market cap in November 2026, QGEN trades at ~19x forward earnings, ~27x trailing earnings and around 15x EV/EBITDA. That prices it as a steady, cash-generative compounder with low-single-digit organic growth, not a high-growth diagnostics name. Analysts' average price target is ~$49.77 across 11 analysts, with a consensus 'hold' rating.

What are the key risks for QGEN?

+

Risks include a persistent QuantiFERON sales drag, exposure to soft academic and pharma research budgets, meaningful currency sensitivity given large non-U.S. sales, intense competition from larger peers, a CEO transition, and acquisition-integration execution. Guidance cuts have shown the top line is vulnerable to demand shocks.

How did QIAGEN do in its latest quarter?

+

For Q3 2026 (ended September 30, 2026), QIAGEN reported sales of ~$548 million, up ~2.9% year over year and above Q2's ~$535 million, with adjusted EPS of $0.65 against a ~$0.63 consensus. Net income was ~$106 million (EPS from continuing operations of $0.51 on a GAAP basis). The next report is expected around February 3, 2027 (date estimated), with analysts expecting ~$570 million of sales and ~$0.66 of adjusted EPS.

How has QGEN stock performed in 2026?

+

As of the 2026-11-20 close near $49.46, QGEN was up ~9.4% year to date and ~8.3% over one year, and up ~13% over the past three months, helped by beats in Q2 and Q3, new FDA clearances and a Barclays upgrade. It slipped ~2% over the past month. Its 52-week range is ~$32.50 to ~$57.80.

Who is QIAGEN's new CEO?

+

At an Extraordinary General Meeting in November 2026, QIAGEN shareholders approved Jonathan M. Pratt as CEO and Managing Director, succeeding Thierry Bernard. Check the company's announcements for the effective date and his priorities for the 2028 plan.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Qiagen N.V.'s investor relations page or your broker before making investment decisions.